Skip to content

Study · Animal study (in vivo) · cat, mouse and rat · 1999

11 results

[The mechanisms of the neurotropic action of bromantan].

Morozov IS, Pukhova GS, Avdulov NA, Sergeeva SA, Spasov AA, Iezhitsa IN

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 1999Cited by 1 (Europe PMC)

PMID10198757 (opens in a new tab)PepBankPUB-10198757
Publisher pageAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, bromantan antagonized neuroleptic effects.

    In plain wordsIn rats, bromantan opposed neuroleptic effects.

    Peptide
    Bromantane
    Outcome
    Not applicableNeuroleptic antagonism
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    5 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    The main components of bromantan central neurotropic effect is its dopamine-positive activity: antagonism (5 mg/kg) to the effects of neuroleptics in rats
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, bromantan affected behavioral responses to 5-hydroxytryptophan without a stated direction.

    In plain wordsIn mice, bromantan affected responses to 5-hydroxytryptophan, but the abstract gives no direction.

    Peptide
    Bromantane
    Outcome
    Direction not reportedResponses to 5-hydroxytryptophan
    Study

    mousen: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1-20 mg/kgAs given in this study (mouse).

    Source sentences

    Summary
    behavior responses to 5-hydroxytryptophan (1-20 mg/kg) in mice
  3. 03AnimalAnimal study (in vivo)Mechanism

    In intact rat brain, low-dose bromantan decreased serotonin content.

    In plain wordsIn rats, low-dose bromantan decreased brain serotonin content.

    Peptide
    Bromantane
    Outcome
    DecreaseBrain serotonin content
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    lower than 5 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    decrease in the mediator content in intact rat brain when administered in doses lower than 5 mg/kg, and the absence of this parameter with the use of higher doses.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In intact rat brain, higher bromantan doses did not produce the serotonin decrease seen at lower doses.

    In plain wordsIn rats, higher bromantan doses did not produce the brain serotonin decrease seen at lower doses.

    Peptide
    Bromantane
    Outcome
    No significant changeBrain serotonin content
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    higher dosesAs given in this study (rat).

    Source sentences

    Summary
    decrease in the mediator content in intact rat brain when administered in doses lower than 5 mg/kg, and the absence of this parameter with the use of higher doses.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In intact rat brain, bromantan did not affect norepinephrine content, unlike sydnocarb.

    In plain wordsIn rats, bromantan did not affect brain norepinephrine content, unlike sydnocarb.

    Peptide
    Bromantane
    Outcome
    No significant changeBrain norepinephrine content
    Study

    ratn: not reported in source

    Comparator
    sydnocarb
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The central noradrenergic effect of the drug is less expressed: blocking of the synaptosomal capture of norepinephrine in higher (more than 500 microM) concentrations), and absence of an effect, in distinction from sydnocarb, 1-5 mg/kg, on the mediator content in intact rat brain.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In cats, intravenous bromantan did not affect neuromuscular transmission.

    In plain wordsIn cats, intravenous bromantan did not affect communication between nerves and muscles.

    Peptide
    Bromantane
    Outcome
    No significant changeNeuromuscular transmission
    Study

    catn: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1-50 mg/kg · intravenouslyAs given in this study (cat).

    Source sentences

    Summary
    The drug (1-50 mg/kg, intravenously) has no effect on neuro-muscular transmission in cats and in higher doses (30-600 mg/kg) inhibits to a certain degree the central effects of nicotine and arecoline.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In animals, higher bromantan doses partly inhibited central nicotine effects.

    In plain wordsIn animals, higher bromantan doses partly inhibited nicotine effects in the brain.

    Peptide
    Bromantane
    Outcome
    DecreaseCentral nicotine effects
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30-600 mg/kgAs given in this study.

    Source sentences

    Summary
    The drug (1-50 mg/kg, intravenously) has no effect on neuro-muscular transmission in cats and in higher doses (30-600 mg/kg) inhibits to a certain degree the central effects of nicotine and arecoline.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In animals, higher bromantan doses partly inhibited central arecoline effects.

    In plain wordsIn animals, higher bromantan doses partly inhibited arecoline effects in the brain.

    Peptide
    Bromantane
    Outcome
    DecreaseCentral arecoline effects
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30-600 mg/kgAs given in this study.

    Source sentences

    Summary
    The drug (1-50 mg/kg, intravenously) has no effect on neuro-muscular transmission in cats and in higher doses (30-600 mg/kg) inhibits to a certain degree the central effects of nicotine and arecoline.
  9. 09LabIn vitro (cells)Mechanism

    In neurons, bromantan inhibited serotonin uptake.

    In plain wordsIn cells, bromantan inhibited serotonin uptake.

    Peptide
    Bromantane
    Outcome
    DecreaseSerotonin uptake
    Study

    n: not reported in source

    neurons
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    50 microMAs given in this study.

    Source sentences

    Summary
    inhibition of neuronal capture of serotonin (50 microM)
  10. 10LabIn vitro (cell-free)Mechanism

    In synaptosomes, bromantan blocked dopamine uptake.

    In plain wordsIn lab tests, bromantan blocked dopamine uptake in synaptosomes.

    Peptide
    Bromantane
    Outcome
    DecreaseDopamine uptake
    Study

    n: not reported in source

    synaptosomes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    50 microMAs given in this study.

    Source sentences

    Summary
    blocking (50 microM) of dopamine synaptosomal capture
  11. 11LabIn vitro (cell-free)Mechanism

    In synaptosomes, bromantan blocked norepinephrine uptake at high concentrations.

    In plain wordsIn lab tests, bromantan blocked norepinephrine uptake at high concentrations.

    Peptide
    Bromantane
    Outcome
    DecreaseNorepinephrine uptake
    Study

    n: not reported in source

    synaptosomes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    more than 500 microMAs given in this study.

    Source sentences

    Summary
    blocking of the synaptosomal capture of norepinephrine in higher (more than 500 microM) concentrations)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.